USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Corvus Pharmaceuticals Expands Socratinib Clinical Pipeline and Announces Third Quarter Results

The Motley Fool · ·by G4L

CRVS
CRVS Corvus Pharmaceuticals Inc
$10.54 +8.32%
View chart & analysis →
  1. 1Corvus Pharmaceuticals announced the expansion of its socratinib clinical pipeline.
  2. 2Corvus recorded $17.8 million in research and development expenses in the third quarter of 2026.
  3. 3Corvus recorded a net loss of $20.3 million in the third quarter of 2026.

So what's the key point?

Corvus Pharmaceuticals decided to broaden the research scope for socratinib. The company spent money on research, recording a net loss of $20.3 million in the third quarter of 2026.

Source The Motley Fool · View original ↗

Related 3-line summaries

Corvus Pharmaceuticals Reports Q3 Loss of $0.22 Per Share Earnings Whispers · 2d ago3 stocks with surging option volume following earnings releases Schaeffer's Research · yesterdayCelcuity Announces Launch of Revtopic and Third Quarter 2026 Financial Results The Motley Fool · yesterday
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news